Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARIS-BIO: Neoadjuvant Darolutamide in High-Risk Prostate Cancer
NCT07617272Phase 2Recruiting
- Sponsor
- Region Stockholm
- Start
- Nov 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Region Stockholm. Started Nov 2025; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07617272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07617272.